Revisiting the transplantation of donor heart with left ventricular myocardial hypertrophy ; К вопросу о трансплантации донорского сердца с гипертрофией миокарда левого желудочка

Συγγραφείς: M. A. Popov, D. V. Shumakov, D. I. Zybin, E. G. Agafonov, М. А. Попов, Д. В. Шумаков, Д. И. Зыбин, Е. Г. Агафонов

Συνεισφορές: The study was performed without external funding., Исследование проводилось без спонсорской поддержки.

Πηγή: Transplantologiya. The Russian Journal of Transplantation; Том 12, № 1 (2020); 42-48 ; Трансплантология; Том 12, № 1 (2020); 42-48 ; 2542-0909 ; 2074-0506 ; 10.23873/2074-0506-2020-12-1

Θεματικοί όροι: терминальная сердечная недостаточность, left ventricular myocardial hypertrophy, expanded criteria organs, expanded criteria donor, terminal heart failure, гипертрофия миокарда левого желудочка, органы с расширенными критериями использования, доноры с расширенными критериями

Περιγραφή αρχείου: application/pdf

Relation: https://www.jtransplantologiya.ru/jour/article/view/478/548; https://www.jtransplantologiya.ru/jour/article/view/478/555; Messerley FH, Williams B, Ritz E. Essential hypertension. Lancet. 2007;370(9587):591–603. PMID: 17707755 https://doi.org/10.1016/s0140-6736(07)61299-9; Mehta SK, Rame JE, Khera A, Murphy SA, Canham RM, Peshock RM, et al. Left ventricular hypertrophy, subclinical atherosclerosis and inflammation. Hypertension. 2007;49(6):1385– 1391. PMID: 17404181 https://doi.org/10.1161/hypertensionaha.107.087890; Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli VP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322(22):1561–1566. PMID: 2139921 https://doi.org/10.1056/nejm199005313222203; Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114(5):345–352. PMID: 1825164 https://doi.org/10.7326/0003-4819-114- 5-345; Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendation for chamber quantification. Eur J Echocardiogr. 2006;7(2):79–108. PMID: 16458610 https://doi.org/10.1016/j.euje.2005.12.014; Russo MJ, Davies RR, Hong KN, Chen JM, Argenziano M, Moskowitz A, et al. Matching high-risk recipients with marginal donor hearts is a clinically effective strategy. Ann Thorac Surg. 2009;87(4):1066–1070. PMID: 19324129 https://doi.org/10.1016/j. athoracsur.2008.12.020; Wever PO, Stoddard G, Drakos SG, Gilbert EM, Nativi JN, Budge D, et al. Impact of donor left ventricular hypertrophy on survival after heart transplant. Am J Transplant. 2011;11(12):2755– 2761. PMID: 21906259 https://doi.org/10.1111/j.1600-6143.2011.03744.x; Khush KK, Menza R, Nguyen J, Zaroff JG, Goldstein BA. Donor predictors of allograft use and recipient outcomes after heart transplantation. Circ Heart Fail. 2013;6(2):300–309. PMID: 23392789 https://doi.org/10.1161/circheartfailure.112.000165; Mohamedali B, Bhat G, Zelinger A. Frequency and pattern of left ventricular dysfunction in potential heart donors: implications regarding use of dysfunctional hearts for successful transplantation. J Am Coll Cardiol. 2012;60(3):235– 236. PMID: 22789890 https://doi.org/10.1016/j.jacc.2012.04.016; Venkateswaran RV, Townend JN, Wilson IC, Mascaro JG, Bonser RS, Steeds RP. Echocardiography in the potential heart donor. Transplantation. 2010;89(7):894–901. PMID: 20075789 https://doi.org/10.1097/tp.0b013e3181cfe8e9; Zaroff JG, Babcock WD, Shi boski SC, Solinger LL, Rosengard BR. Temporal changes in left ventricular systolic function in heart donors: results of serial echocardiography. J Heart Lung Transplant. 2003;22(4):383–388. PMID: 12681416 https://doi.org/10.1016/s1053-2498(02)00561-2; Chen CW, Sprys MH, Gaffey AC, Chung JJ, Margulies KB, Acker MA, et al. The low ejection fraction in donor hearts is not directly related to increase recipient mortality. J Heart Lung Transplant. 2017;36(6):611– 615. PMID: 28314504 https://doi.org/10.1016/j.healun.2017.02.001; Marelli D, Laks H, Fazio D, Moore S, Moriguchi J,Kobashigawa J. The use of donor hearts with left ventricular hypertrophy. J Heart Lung Transplant. 2000;19(5):496–503. PMID: 10808159 https://doi.org/10.1016/s1053-2498(00)00076-0; Aziz S, Soine LA, Lewis SL, Kruse AP, Levy WC, Wehe KM, et al. Donor left ventricular hypertrophy increases risk for early graft failure. Transpl Int. 1997;10(6):446–450. PMID: 9428118 https://doi.org/10.1007/s001470050084; Goland S, Czer LS, Kass RM, Siegel RJ, Mirocha J, De Robertis MA, et al. Use of cardiac allografts with mild and moderate left ventricular hypertrophy can be safely used in heart transplantation to expand the donor pool. J Am Coll Cardiol. 2008;51(12):1214– 1220. PMID: 18355661 https://doi.org/10.1016/j.jacc.2007.11.052; Kittleson M, Patel J, Chang DH, Kransdorf E, Levine R, Dimbil S, et al. Donor left ventricular hypertrophy: over-rated or does donor history of hypertension make a difference for post-heart transplant outcome? J Heart Lung Transplantation. 2019;38(4 Suppl):S269. https://doi.org/10.1016/j. healun.2019.01.670; Stetson SJ, Perez-Verdia A, Mazur W, Farmer JA, Koerner MM, Weilbacher DG, et al. Cardiac hypertrophy after transplantation is associated with persistent expression of tumor necrosis factor-. Circulation. 2001;104(6):676–681. https://doi.org/10.1161/hc3101.093765; Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. Tumor necrosis factor- provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 1997;95(5):1247–1252. PMID: 9054856 https://doi.org/10.1161/01.cir.95.5.1247; McKoy RC, Uretsky BF, Kormos R, Hardesty RL, Griffith BP, Salerni R, et al. Left ventricular hypertrophy in cyclosporine-induced systemic hypertension after cardiac transplantation. Am J Cardiol. 1988;62(4):1140– 1142. PMID: 2973223 https://doi.org/10.1016/0002-9149(88)90570-x; Ventura HO, Lavie CJ, Messerli FH, Valentino V, Smart FW, Stapleton DD, et al. Cardiovascular adaptation to cyclosporine-induced hypertension. J Hum Hypertens. 1994;8(4):233–237. PMID: 8021902; Calò L, Semplicini A, Davis PA, Bonvicini P, Cantaro S, Rigotti P, et al. Cyclosporin-induced endothelial dysfunction and hypertension: are nitric oxide system abnormality and oxidative stress involved? Transplant Int. 2000;13(Suppl 1):413–418. PMID: 11112045 https://doi.org/10.1007/s001470050374; Taler SJ, Textor SC, Canzanello VJ, Schwartz L. Cyclosporine-Induced Hypertension: incidence, pathogenesis and management. Drug Safety. 1999;20(5):437–449. PMID: 10348094 https://doi.org/10.2165/00002018- 199920050-00004; Goodroe R, Bonnema DD, Lunsford S, Anderson P, Ryan-Baille B, Uber W, et al. Severe left ventricular hypertrophy 1 year after transplant predicts mortality in cardiac transplant recipients. J Heart Lung Transplant. 2007;26(2):145– 151. PMID: 17258148 https://doi.org/10.1016/j.healun.2006.11.003; Morgan JA, John R, Weinberg AD, Remoli R, Kherani AR, Vigilance DW, et al. Long-term results of cardiac transplantation in patients 65 years of age and older: a comparative analysis. Ann Thorac Surg. 2003;76(6):1982–1987. PMID: 14667625 https://doi.org/10.1016/s0003-4975(03)01070-1; Everett JE, Djalilian AR, Kubo SH, Kroshus TJ, Shumway SJ. Heart transplantation for patients over age 60. Clin Transplant. 1996;10(6Pt1):478–81. PMID: 8996766; Blanche C, Blanche DA, Kearney B, Sandhu M, Czer LS, Kamlot A, et al. Heart transplantation in patients seventy years of age and older: A comparative analysis of outcome. J Thorac Cardiovasc Surg. 2001;121(3):532–541. PMID: 11241089 https://doi.org/10.1067/mtc.2001.112831; Marelli D, Bresson J, Laks H, Kubak B, Fonarow G, Tsai FC, et al. Hepatitis C-positive donors in heart transplantation. Am J Transplant. 2002;2(5):443– 447. PMID: 12123210 https://doi.org/10.1034/j.1600-6143.2002.20508.x; Laks H, Marelli D, Fonarow GC, Hamilton MA, Ardehali A, Moriguchi JD, et al. Use of two recipient lists for adults requiring heart transplantation. J Thorac Cardiovasc Surg. 2003;125(1):49–59. PMID: 12538985 https://doi.org/10.1067/mtc.2003.62; Laks H, Marelli D. The alternate recipient list for heart transplantation: a model for expansion of the donor pool. Adv Card Surg. 1999;11:233–244. PMID: 10575495; Шевченко А.О., Фараджов Р.А., Изотов Д.А., Колоскова Н.Н., Никитина Е.А., Гичкун О.Е. и др. Ингибиторы ангиотензинпревращающего фермента у реципиентов сердца: результаты одноцентрового исследования. Вестник трансплантологии и искусственных органов. 2018;20(4):14–21.; Попцов В.Н., СпиринаЕ.А., Устин С.Ю., Масютин С.А., Догонашева А.А., Воронков В.Ю. и др. Трансплантация донорского сердца с гипертрофией миокарда левого желудочка 1,5 см и более. Вестник трансплантологии и искусственных органов. 2019;21(1):7–16.; https://www.jtransplantologiya.ru/jour/article/view/478

Διαθεσιμότητα: https://www.jtransplantologiya.ru/jour/article/view/478
https://doi.org/10.23873/2074-0506-2020-12-1-42-48